Success Metrics

Clinical Success Rate
100.0%

Based on 11 completed trials

Completion Rate
100%(11/11)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
15%
Ph phase_4
3
23%
Ph phase_2
2
15%
Ph not_applicable
5
38%
Ph phase_1
1
8%

Phase Distribution

1

Early Stage

2

Mid Stage

5

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
1(7.7%)
Phase 2Efficacy & side effects
2(15.4%)
Phase 3Large-scale testing
2(15.4%)
Phase 4Post-market surveillance
3(23.1%)
N/ANon-phased studies
5(38.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

11 of 11 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(11)
Other(2)

Detailed Status

Completed11
unknown2

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (7.7%)
Phase 22 (15.4%)
Phase 32 (15.4%)
Phase 43 (23.1%)
N/A5 (38.5%)

Trials by Status

completed1185%
unknown215%

Recent Activity

Clinical Trials (13)

Drug Details

Intervention Type
DRUG
Total Trials
13